GWPH
GW Pharmaceuticals Meets Q4 Revenue Guidance but Losses No Bueno
Cannabis drug provider GW Pharmaceuticals (NASDAQ: GWPH) reported earnings that severely disappointed against investor's expectations The market will likely be…
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Jan 18th, 2020)
A weekly review of only the most important marijuana news to impact your marijuana stocks portfolio.
GW Pharmaceuticals Releases a Q4 Revenue Beat, but Will the Rapid Growth Continue?
Bottom Line Cannabinoid prescription medicine company GW Pharmaceuticals (NASDAQ: GWPH) pre-announced revenues for its fourth quarter and full-year last night.…
EU Approves Epidyolex to Treat Severe Epilepsy in Children
The European Union has approved its first medical cannabis product in order to help doctors across the continent treat children…
Earnings Update: Second GW Pharmaceuticals Stock Price Increase After February’s Alzheimer’s Trial News
GW Pharmaceuticals (NASDAQ: GWPH) has been on a tear over the past month after exceeding expectations with its Q4 results, which were…
Epidiolex Maker GW Pharmaceuticals Raises $345 Million Through Share Sale
British medicinal marijuana producer GW Pharmaceuticals (NASDAQ: GWPH) has raised $345 million to fund an expansion drive after releasing 2.18…
Investing in Medical Marijuana Stocks – Quantifying the Upside
The argument for marijuana as a legitimate medicine is rapidly gaining momentum as more and more clinical studies are released.…